导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.04% | 2429/4773 |
| 近一周 | -2.10% | 3386/5465 |
| 近一月 | -6.53% | 4218/5421 |
| 近一季 | -13.54% | 4163/5231 |
| 近半年 | -4.83% | 2944/4920 |
| 近一年 | 3.00% | 2159/4394 |
| 近两年 | 69.09% | 1034/2954 |
| 近三年 | 35.59% | 892/2253 |
| 成立以来 | 94.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.84% 1983/4961 |
21.51% 1169/5312 |
- - |
- - |
| 2025 | 31.16% 1259/4813 |
0.20% 1952/3635 |
0.37% 2675/4076 |
31.55% 1115/4524 |
-0.86% 2688/4813 |
| 2024 | 11.13% 1344/3463 |
-0.66% 1135/2808 |
-4.43% 1504/3014 |
19.85% 799/3129 |
-2.34% 2048/3463 |
| 2023 | -14.50% 1606/2656 |
5.45% 783/2280 |
-5.45% 1460/2385 |
-8.29% 1689/2515 |
-6.49% 1801/2655 |
| 2022 | -25.65% 1336/2207 |
-18.78% 1394/1919 |
7.76% 432/2016 |
-16.52% 1465/2113 |
1.76% 1157/2208 |
| 2021 | 0.73% 707/1822 |
-5.18% 909/1255 |
10.65% 445/1330 |
-6.71% 982/1466 |
2.92% 495/1822 |
| 2020 | 42.45% 268/1250 |
-5.08% 398/1028 |
21.37% 233/1067 |
8.40% 715/1164 |
14.07% 300/1184 |
| 2019 | 47.43% 121/1092 |
36.67% 82/754 |
-5.91% 488/804 |
3.81% 231/850 |
10.44% 131/918 |
| 2018 | -33.95% 561/834 |
- - |
- - |
- - |
-13.90% 562/691 |
| 2017 | 13.80% 259/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.93% 428/605 |
- - |
- - |
- - |
- - |
| 2015 | 32.55% 70/575 |
- - |
- - |
- - |
- - |
| 2014 | 30.29% 163/237 |
- - |
- - |
- - |
- - |
| 2013 | 4.85% 54/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.51% 95/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 汇添富深证300ETF VS. 长安沪深300非周期A(740101) |